Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma

The identification of BRAF V600 mutation in multiple cancers beyond melanoma and the development of combined BRAF and MEK targeting agents have altered the landscape of tissue-agnostic precision oncology therapies with an impact on survival outcomes. Despite initial efficacy, resistance emerges, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Blessie Elizabeth, Reddy, Neha K., Huse, Jason T., Amini, Behrang, Nardo, Mirella, Gouda, Mohamed, Weathers, Shiao-Pei, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212928/
https://www.ncbi.nlm.nih.gov/pubmed/37231247
http://dx.doi.org/10.1038/s41698-023-00398-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212928/
https://www.ncbi.nlm.nih.gov/pubmed/37231247
http://dx.doi.org/10.1038/s41698-023-00398-5

Ejemplares similares